Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Aug;72(2):648–655. doi: 10.1172/JCI111014

Metabolic compensation for profound erythrocyte adenylate kinase deficiency. A hereditary enzyme defect without hemolytic anemia.

E Beutler, D Carson, H Dannawi, L Forman, W Kuhl, C West, B Westwood
PMCID: PMC1129224  PMID: 6308059

Abstract

A child with hemolytic anemia was found to have severe erythrocyte adenylate kinase (AK) deficiency, but an equally enzyme-deficient sibling had no evidence of hemolysis. No residual enzyme activity was found in erythrocytes by spectrophotometric methods that could easily have detected 0.1% of normal activity. However, concentrated hemolysates were shown to have the capacity to generate small amounts of ATP and AMP from ADP after prolonged incubation. Hemolysates could also catalyze the transfer of labeled gamma-phosphate from ATP to ADP. Intact erythrocytes were able to transfer phosphate from the gamma-position of ATP to the beta-position, albeit at a rate substantially slower than normal. They could also incorporate 14C-labeled adenine into ADP and ATP. Thus, a small amount of residual AK-like activity representing about 1/2,000 of the activity normally present could be documented in the deficient erythrocytes. The residual activity was not inhibited by N-ethylmaleimide, which completely abolishes the activity of the normal AK1 isozyme of erythrocytes. The minute amount of residual activity in erythrocytes could represent a small amount of the AK2 isozyme, which has not been thought to be present in erythrocytes, or the activity of erythrocyte guanylate kinase with AMP substituting as substrate for GMP. Peripheral blood leukocytes, cultured skin fibroblasts, and transformed lymphoblasts from the deficient subject manifested about 17, 24, and 74%, respectively, of the activity of the concurrent controls. This residual activity is consistent with the existence of genetically independent AK isozyme, AK2, which is known to exist in these tissues. The cause of hemolysis in the proband was not identified. Possibilities include an unrelated enzyme deficiency or other erythrocyte enzyme defect and intraction of another unidentified defect with AK deficiency.

Full text

PDF
648

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal K. C., Parks R. E., Jr Adenosine triphosphate-guanosine 5'-phosphate phosphotransferase. IV. Isozymes in human erythrocytes and Sarcoma 180 ascites cells. Mol Pharmacol. 1972 Mar;8(2):128–138. [PubMed] [Google Scholar]
  2. BARTLETT G. R. Methods for the isolation of glycolytic intermediated by column chromatography with ion exchange resins. J Biol Chem. 1959 Mar;234(3):459–465. [PubMed] [Google Scholar]
  3. Bartlett G. R. Phosphorus compounds in the human erythrocyte. Biochim Biophys Acta. 1968 Mar 11;156(2):221–230. doi: 10.1016/0304-4165(68)90251-1. [DOI] [PubMed] [Google Scholar]
  4. Beutler E., Guinto E. A simple, rapid, efficient method for the preparation of gamma 32P-labeled guanosine triphosphate (GTP) and adenosine triphosphate (ATP). J Lab Clin Med. 1976 Sep;88(3):520–524. [PubMed] [Google Scholar]
  5. Beutler E., Guinto E., Kuhl W., Matsumoto F. Existence of only a single functional pool of adenosine triphosphate in human erythrocytes. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2825–2828. doi: 10.1073/pnas.75.6.2825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beutler E. Red cell enzyme defects as nondiseases and as diseases. Blood. 1979 Jul;54(1):1–7. [PubMed] [Google Scholar]
  7. Beutler E., West C., Blume K. G. The removal of leukocytes and platelets from whole blood. J Lab Clin Med. 1976 Aug;88(2):328–333. [PubMed] [Google Scholar]
  8. Boivin P., Galand C., Demartial M. C. Erythroenzymopathies acquises. II. Déficit en adénylate-kinase au cours des hémopathies. Pathol Biol (Paris) 1972 Oct;20(19):781–784. [PubMed] [Google Scholar]
  9. Boivin P., Galand C., Hakim J., Simony D., Seligman M. Déficit congénital en adénylate-kinase érythrocytaire. Presse Med. 1970 Jun;78(32):1443–1443. [PubMed] [Google Scholar]
  10. Boivin P., Galand C., Hakim J., Simony D., Seligman M. Une nouvelle érythroenzymopathie: anémie hémolytique congénitale non sphérocytaire et déficit héréditaire en adénylate-kinase érytrocytaire. Presse Med. 1971 Jan 30;79(6):215–218. [PubMed] [Google Scholar]
  11. Khoo J. C., Russell P. J. Isoenzymes of adenylate kinase in human tissue. Biochim Biophys Acta. 1972 Apr 7;268(1):98–101. doi: 10.1016/0005-2744(72)90202-1. [DOI] [PubMed] [Google Scholar]
  12. McKusick V. A., Ruddle F. H. The status of the gene map of the human chromosomes. Science. 1977 Apr 22;196(4288):390–405. doi: 10.1126/science.850784. [DOI] [PubMed] [Google Scholar]
  13. Russell P. J., Jr, Horenstein J. M., Goins L., Jones D., Laver M. Adenylate kinase in human tissue. I. Organ specificity of adenylate kinase isoenzymes. J Biol Chem. 1974 Mar 25;249(6):1874–1879. [PubMed] [Google Scholar]
  14. Slaughter L., Carson D. A., Jensen F. C., Holbrook T. L., Vaughan J. H. In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med. 1978 Nov 1;148(5):1429–1434. doi: 10.1084/jem.148.5.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Szeinberg A., Gavendo S., Cahane D. Erythrocyte adenylate-kinase deficiency. Lancet. 1969 Feb 8;1(7589):315–316. doi: 10.1016/s0140-6736(69)91080-0. [DOI] [PubMed] [Google Scholar]
  16. Wilson D. E., Povey S., Harris H. Adenylate kinases in man: evidence for a third locus. Ann Hum Genet. 1976 Jan;39(3):305–313. doi: 10.1111/j.1469-1809.1976.tb00134.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES